WXSH 0081
Alternative Names: WXSH-0081Latest Information Update: 28 May 2024
At a glance
- Originator Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in China (PO, Tablet)
- 26 Apr 2020 Preclinical trials in Inflammatory bowel diseases in China (PO)
- 26 Apr 2020 Shijiazhuang Zhikang Hongren New Drug Development plans a phase I trial for Inflammatory bowel diseases (In volunteers) in China (PO) (ChiCTR2000032290)